KIORA PHARMACEUTICALS INC — Director's Dealing 2016

Mar 31, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2016-03-29

Reporting Person: Wirostko Barbara (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-29	Stock Option (right to buy)	$3.06	A	3431	Acquired	2026-03-29	Common Stock (3431)	Direct

Footnotes

F1: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on March 29, 2017, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.